% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Akeret:302835,
author = {K. Akeret and L. Padevit and G. Reifenberger$^*$ and A. von
Deimling$^*$ and M. Weller and E. Le Rhun},
collaboration = {H. G. D. S. Group},
title = {{A}natomic {S}taging of {H}3 {G}34-{M}utant {D}iffuse
{H}emispheric {G}lioma.},
journal = {Neurology},
volume = {105},
number = {3},
issn = {0028-3878},
address = {Philadelphia, Pa.},
publisher = {Wolters Kluwer},
reportid = {DKFZ-2025-01375},
pages = {e213861},
year = {2025},
abstract = {H3 G34-mutant diffuse hemispheric gliomas are rare,
aggressive primary brain tumors predominantly affecting
young patients. We investigated the prognostic value of
anatomic staging (AS)-a system previously validated in
adult-type diffuse gliomas-in this molecularly distinct
tumor type.Patients from an international cohort with H3
G34-mutant gliomas underwent AS based on pretreatment
imaging, performed independently by 2 raters blinded to
clinical outcomes. Inter-rater reliability was evaluated
using Cohen kappa. Kaplan-Meier curves and Cox proportional
hazards models-unadjusted and adjusted for sex, extent of
resection, and O6-methylguanine DNA-methyltransferase (MGMT)
status-were used to analyze overall survival across
stages.Thirty-seven patients were included (median age 22
years; $54\%$ female). Inter-rater reliability was high
(weighted κ = 0.93, $95\%$ CI 0.85-1.0). Median overall
survival was 36 months for stage 1 $(95\%$ CI 16-67 months),
25 months for stage 2 $(95\%$ CI 8-41), and 9 months for
stage 3 $(95\%$ CI 3-26). After adjustment for sex, extent
of resection, and MGMT status, survival differences
persisted (hazard ratio [HR]Stage 2 adjusted 2.25, $95\%$ CI
0.67-7.5, p = 0.19; HRStage 3 adjusted 4.37, $95\%$ CI
1.39-13.7, p = 0.01).AS is reproducible and prognostically
relevant for H3 G34-mutant gliomas, providing insights into
tumor spread. It may inform treatment decisions, but larger
studies are needed to confirm its clinical utility.},
keywords = {Humans / Female / Male / Glioma: genetics / Glioma:
pathology / Glioma: diagnostic imaging / Glioma: mortality /
Brain Neoplasms: genetics / Brain Neoplasms: pathology /
Brain Neoplasms: diagnostic imaging / Brain Neoplasms:
mortality / Adult / Young Adult / Mutation: genetics /
Histones: genetics / Neoplasm Staging / Adolescent / Middle
Aged / Prognosis / Cohort Studies / Kaplan-Meier Estimate /
DNA Modification Methylases: genetics / Histones (NLM
Chemicals) / DNA Modification Methylases (NLM Chemicals)},
cin = {B300 / HD01 / ED01},
ddc = {610},
cid = {I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)ED01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40638885},
doi = {10.1212/WNL.0000000000213861},
url = {https://inrepo02.dkfz.de/record/302835},
}